Which sedative is safer for sleep apnea patients during endoscopy?

NCT ID NCT07459322

Not yet recruiting Symptom relief Sponsor: Fu Jen Catholic University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This study will compare two sedative drugs, remimazolam and dexmedetomidine, in 60 adults with obstructive sleep apnea undergoing drug-induced sleep endoscopy. The goal is to see which drug provides more stable sedation, fewer side effects like low heart rate or low blood pressure, and faster recovery. Researchers will also use artificial intelligence to analyze sleep study data to better predict airway blockages.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Remimazolam and Dexmedetomidine
What this could lead to: If successful, this could help doctors choose the safer, more effective sedative for sleep endoscopy, improving patient comfort and reducing complications.
What could go wrong: This is a small, early-stage study (60 participants) comparing two drugs for a diagnostic procedure, not a treatment for sleep apnea itself. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DISE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DISE OSAS (OBSTRUCTIVE SLEEP APNEAS SYNDROME) SEDATION

Contacts and locations

Locations

Fu Jen Catholic University Hosptial

New Taipei City, Taiwan (r.o.c.), 24352, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.